Switchpoint Bio has secured €4.75 million in funding to advance its epigenomic platform. The investment round was led by Treehouse Delmar Investments, which contributed €4.48 million, equivalent to $5 million.
The startup was founded in 2025 by Samuel Myllykangas and Jason Buenrostro. The team also includes co-founders Niilo Färkkilä, Jussi Paananen, and Mitja Kurki. The founders previously collaborated at Stanford University.
The company is developing a platform that uses targeted DNA methylation profiling from blood samples. By combining epigenomic profiling with AI, the technology aims to track how diseases and drug treatments affect human biology.
Switchpoint Bio is currently transitioning from platform development to clinical and industry validation. The company is testing its approach on autoimmune conditions, such as systemic lupus erythematosus, to monitor immune states over time.
The new capital will be used to expand clinical and biobank datasets, further develop the AI platform, and grow the scientific and technical teams based in Helsinki and Cambridge.
